The price of Charles River Laboratories International Inc (NYSE:CRL) shares last traded on Wall Street fell -0.20% to $99.75.
CRL stock price is now -36.94% away from the 50-day moving average and -46.77% away from the 200-day moving average. The market capitalization of the company currently stands at $4.90B.
With the price target reduced from $190 to $170, Goldman Downgraded its rating from Buy to Neutral for Charles River Laboratories International Inc (NYSE: CRL). On March 04, 2025, Citigroup Upgraded its previous ‘Sell’ rating to ‘Neutral’ on the stock increasing its target price from $155 to quote $175, while ‘Redburn Atlantic’ rates the stock as ‘Neutral’
In other news, FOSTER JAMES C, Chairman, President and CEO bought 6,075 shares of the company’s stock on Feb 20 ’25. The stock was bought for $1,002,436 at an average price of $165.01. Upon completion of the transaction, the Chairman, President and CEO now directly owns 183,639 shares in the company, valued at $18.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’25, Corporate Executive VP & COO Girshick Birgit bought 1,514 shares of the business’s stock. A total of $249,250 was incurred on buying the stock at an average price of $164.63. This leaves the insider owning 55,058 shares of the company worth $5.49 million. A total of 1.12% of the company’s stock is owned by insiders.
During the past 12 months, Charles River Laboratories International Inc has had a low of $95.97 and a high of $254.15. As of last week, the company has a debt-to-equity ratio of 0.80, a current ratio of 1.41, and a quick ratio of 1.13. According to the stock market information, the enterprise value for the company is $7734426112, which is based on a 388.89 price-to-earnings ratio, a 142.45 price-to-earnings-growth ratio, and a beta of 1.60. The fifty day moving average price for CRL is $158.1886 and a two-hundred day moving average price translates $187.3933 for the stock.
The latest earnings results from Charles River Laboratories International Inc (NYSE: CRL) was released for 2024-12-28. The net profit margin was 0.39% and return on equity was 0.45% for CRL. The company reported revenue of $1.0 billion for the quarter, compared to $1.01 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.08 percent.
